巨细胞动脉炎托珠单抗治疗是否存在机会窗?471例多中心研究
该多中心观察性研究纳入471例接受托珠单抗治疗的巨细胞动脉炎患者,按诊断至用药时间分为新诊断组(≤6周)和难治组(>6周)。以6周为界未发现机会窗,但将时间作为连续变量分析时,托珠单抗启动越早与24个月EULAR缓解率越高相关(OR 0.983)。
要点
- 以6周为界划分新诊断与难治组,24个月缓解、器官损伤及复发率无显著差异。
- 按连续时间分析,托珠单抗启动越早与24个月EULAR缓解率越高独立相关(OR 0.983)。
- 启动时间与累积器官损伤及复发无显著关联。
核心结论
- 以临床试验常用6周界值未识别出托珠单抗治疗巨细胞动脉炎的机会窗,但诊断后更早启动托珠单抗与24个月EULAR缓解率更高相关。
研究设计与样本
- 多中心观察性研究纳入471例接受托珠单抗治疗的巨细胞动脉炎患者,按诊断至启动托珠单抗时间分为新诊断组(≤6周,91例)和难治组(>6周,380例)。
主要发现
- 471例患者中女性占72.6%,平均年龄73.5±9岁,新诊断组91例(19.3%),难治组380例(80.7%)。
- 两组在24个月EULAR定义的缓解、累积器官损伤及复发率方面均无显著差异。
- 将诊断至托珠单抗启动时间作为连续变量分析,较短时间与24个月EULAR缓解显著相关(OR 0.983;95%CI 0.967-0.999;p=0.035)。
- 连续时间变量与器官损伤或复发无显著关联。
关键数值与推荐
- 新诊断组定义为诊断后≤6周启动托珠单抗,难治组定义为>6周启动。
- 24个月EULAR缓解与更早启动托珠单抗的连续时间变量相关:OR 0.983(95%CI 0.967-0.999;p=0.035)。
临床怎么用
- 对于巨细胞动脉炎患者,在诊断后尽早启动托珠单抗可能提高24个月EULAR缓解机会,但以6周为界的机会窗概念未获支持。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tocilizumab (TCZ) is currently the first biological drug approved for the treatment of giant cell arteritis (GCA), regardless of disease stage or phenotype. The window of opportunity, a critical period for early intervention, is increasingly recognized in immune-mediated inflammatory disorders (IMIDs). OBJECTIVES: To assess whether there was a window of opportunity at the classic cut-off point used in clinical trials (e.g., GiACTA). PATIENTS AND METHODS: Multicenter observational study of 471 patients with GCA treated with TCZ. Patients were stratified into two groups: Newly Diagnosed (TCZ ≤6 weeks from diagnosis) and Refractory (>6 weeks). Timing effects were assessed using multivariable regression models adjusted for potential confounding factors, evaluating both the dichotomous variable "newly diagnosed GCA" and the continuous variable "time from GCA diagnosis to TCZ initiation"; multiple time cut-offs were also analyzed following the same methodological approach. RESULTS: Of the 471 patients (72.6 % female; mean age 73.5 ± 9 years), 91 (19.3 %) were classified as newly diagnosed and 380 (80.7 %) as refractory. No significant differences were observed in EULAR-defined remission, cumulative organic damage, or relapse rates after 24 months of TCZ. Using the continuous variable "time from GCA diagnosis to TCZ initiation", a significant association was observed between shorter time to TCZ initiation and EULAR remission at 24 months (OR 0.983; 95 % CI 0.967-0.999; p = 0.035), whereas no significant associations were found for organ damage or relapses. CONCLUSIONS: Although no clear window of opportunity was identified using the classic cut-off for TCZ initiation in GCA (≤6 weeks), an earlier initiation of TCZ after diagnosis appears to be associated with a higher likelihood of remission in patients with GCA.
引用
- Martín-Gutiérrez A, Loricera J, Prieto-Peña D, et al. Is there a window of opportunity in the treatment of giant cell arteritis with tocilizumab? Multicenter study of 471 patients. Semin Arthritis Rheum. 2026. PMID: 41887029. doi:10.1016/j.semarthrit.2026.152955
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。